Effects of secukinumab on metabolic and liver parameters in plaque psoriasis patients.

ABSTRACT:

Background

Psoriasis is associated with metabolic, liver and cardiovascular comorbidity. Secukinumab, a fully human monoclonal antibody that selectively neutralizes interleukin-17A, has shown significant and sustained efficacy in the treatment of moderate to severe psoriasis.

Objectives

This was an exploratory post hoc analysis of pooled data from three phase 3 studies in plaque psoriasis patient populations. The objective was to show the course of metabolic and liver parameters under secukinumab, etanercept or placebo treatment over time. A further objective was to assess the impact of selected comorbidities and metabolic characteristics on high-sensitivity C-reactive protein (hs-CRP), as a surrogate marker of systemic inflammation.

Methods

Data from the phase 3 rand

SUBMITTER: Gerdes S 

PROVIDER: S-EPMC7065121 | biostudies-literature | 2020 Mar

REPOSITORIES: biostudies-literature